PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2022.03.016

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (3): 278-282.doi: 10.11904/j.issn.1002-3070.2022.03.016

PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展

童曼琳¹, 尚茹茹² 综述, 刘晓红¹ 审校

1.山西医科大学第五临床医学院特需病房(太原 030001);
2.山西省人民医院特需病房

收稿日期:2021-12-19 修回日期:2022-02-22 出版日期:2022-06-28 发布日期:2022-06-28
通讯作者: 刘晓红,E-mail:docliuxh@163.com
作者简介:童曼琳,女,(1994-),硕士研究生,从事胶质瘤相关的研究。

Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme

TONG Manlin¹, SHANG Ruru², LIU Xiaohong¹

1. The VIP wards of the Department of the Fifth Clinical Medical College of Shanxi Medical University,Taiyuan 030001,China;
2. The VIP Wards of the Department of Shanxi Provincial People′s Hospital

Received:2021-12-19 Revised:2022-02-22 Online:2022-06-28 Published:2022-06-28

摘要/Abstract

摘要： 多形性胶质母细胞瘤(Glioblastoma multiforme,GBM)是目前最常见的原发性恶性脑肿瘤之一。GBM具有高侵袭性、高复发率和低生存率等特点,预后较差。程序性细胞死亡受体1(Programmed cell death receptor 1,PD-1)/程序性细胞死亡配体1(Programmed cell death ligand 1,PD-L1)作为主要的免疫检查点(Immune checkpoint,IC),形成免疫通路,可触发免疫反应的负性调控,增强脑组织中GBM细胞的侵袭性。在GBM的治疗研究中,免疫检查点抑制剂(Immune checkpoint inhibitor,ICI)也受到了相当大的关注。ICI通过抑制负性免疫调节途径来激活抗肿瘤反应,为GBM提供了新的治疗途径。目前已有多项临床研究集中在标准治疗(替莫唑胺、放疗)、靶向治疗和其他免疫治疗的联合应用方面。本综述阐述了PD-1/PD-L1通路,概述了PD-1/PD-L1 ICI单药、新辅助治疗以及联合化疗、放疗、靶向治疗、激素等多种方式治疗GBM的研究进展。

关键词: 胶质母细胞瘤, 程序性死亡受体-1, 免疫治疗

Abstract: Glioblastoma multiforme(GBM)is one of the most common primary malignant brain tumors.GBM has the characteristics of high invasiveness,high recurrence rate and low survival rate,with a poor prognosis.Programmed cell death receptor 1(PD-1)/programmed cell death ligand 1(PD-L1)as the main immune checkpoint(IC),the formation of immune pathways can trigger negative regulation of immune response and enhance the invasiveness of GBM cells in brain tissue.Research into GBM treatment is ongoing,and immune checkpoint inhibitors(ICIs)have also received considerable attention.ICIs activate antitumor response by inhibiting negative immunoregulatory pathways,providing a new therapeutic approach for GBM.Several clinical studies have focused on the combination of standard therapy(temozolomide,radiotherapy),targeted therapy,and other immunotherapies.This review describes the PD-1/PD-L1 pathways,and summarizes the research progress of PD-1/PD-L1 monotherapy,neoadjuvant therapy and combined chemotherapy,radiotherapy,targeted therapy,hormones,etc.in the treatment of GBM.

Key words: Glioblastoma, Programmed death receptor-1, Immunotherapy

中图分类号:

R739.4

童曼琳, 尚茹茹, 刘晓红. PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 278-282.

TONG Manlin, SHANG Ruru, LIU Xiaohong. Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme[J]. Journal of Practical Oncology, 2022, 36(3): 278-282.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.03.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I3/278

参考文献

1 Ostrom QT,Gittleman H,Truitt G,et al.CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015[J].Neuro Oncol,2018,20(suppl 4):1-86.
2 Jiang T,Mao Y,Ma W,et al.CGCG clinical practice guidelines for the management of adult diffuse gliomas[J].Cancer Lett,2016,375(2):263-273.
3 Li B,Chan HL,Chen P.Immune checkpoint inhibitors:basics and challenges[J].Curr Med Chem,2019,26(17):3009-3025.
4 Maghrouni A,Givari M,Jalili-Nik M,et al.Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme:Preclinical evidence and clinical interventions[J].Int Immunopharmacol,2021,93:107403.
5 Han Y,Liu D,Li L.PD-1/PD-L1 pathway:current researches in cancer[J].Am J Cancer Res,2020,10(3):727-742.
6 Jiang Y,Chen M,Nie H,et al.PD-1 and PD-L1 in cancer immunotherapy:clinical implications and future considerations[J].Hum Vaccin Immunother,2019,15(5):1111-1122.
7 Messenheimer DJ,Jensen SM,Afentoulis ME,et al.Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-ox40[J].Clin Cancer Res,2017,23(20):6165-6177.
8 Wang X,Guo G,Guan H,et al.Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma[J].J Exp Clin Cancer Res,2019,38(1):87.
9 Sun C,Mezzadra R,Schumacher TN.Regulation and function of the PD-L1 checkpoint[J].Immunity,2018,48(3):434-452.
10 Tang J,Yu JX,Hubbard-Lucey VM,et al.Trial watch:The clinical trial landscape for PD-1/PD-L1 immune checkpoint inhibitors[J].Nat Rev Drug Discov,2018,17(12):854-855.
11 Ott PA,Bang YJ,Piha-Paul SA,et al.T-cell-inflamed gene expression profile,programmed death ligand 1 expression,and tumor mutational burden predict efficacy in patients treated with pembrolizumab cross 20 cancers:KEYNOTE-028[J].J Clin Oncol,2019,37(4):318-327.
12 Kurz SC,Cabrera LP,Hastie D,et al.PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma[J].Neurology,2018,91(14):1355-1359.
13 Lukas RV,Rodon J,Becker K,et al.Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma[J].J Neuro Oncol,2018,140(2):317-328.
14 Yang T,Kong Z,Ma W.PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma:clinical studies,challenges and potential[J].Hum Vaccin Immunother,2021,17(2):546-553.
15 Berghoff AS,Kiesel B,Widhalm G,et al.Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma[J].Neuro Oncol,2015,17(8):1064-1075.
16 Galon J,Bruni D.Approaches to treat immune hot,altered and cold tumours with combination immunotherapies[J].Nat Rev Drug Discov,2019,18(3):197-218.
17 Antonios JP,Soto H,Everson RG,et al.Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma[J].Neuro Oncol,2017,19(6):796-807.
18 Berghoff AS,Preusser M.Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?[J].Nat Rev Neurol,2019,15(6):314-315.
19 Schalper KA,Rodriguez-Ruiz ME,Diez-Valle R,et al.Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma[J].Nat Med,2019,25(3):470-476.
20 Cloughesy TF,Mochizuki AY,Orpilla JR,et al.Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma[J].Nat Med,2019,25:477-486.
21 Wang S,Yao F,Lu X,et al.Temozolomide promotes immune escape of GBM cells via upregulating PD-L1[J].Am J Cancer Res,2019,9(6):1161-1171.
22 Karachi A,Yang C,Dastmalchi F,et al.Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition[J].Neuro Oncol,2019,21(6):730-741.
23 Newcomb EW,Demaria S,Lukyanov Y,et al.The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas[J].Clin Cancer Res,2006,12:4730-4737.
24 Zeng J,See AP,Phallen J,et al.Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J].Int J Radiat Oncol Biol Phys,2013,86(2):343-349.
25 Diaz RJ,Ali S,Qadir MG,et al.The role of bevacizumab in the treatment of glioblastoma[J].J Neurooncol,2017,133(3):455-467.
26 Tamura R,Tanaka T,Ohara K,et al.Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab[J].Cancer Sci,2019,110(2):499-508.
27 Reardon DANL,Peters KB,Peters KB,et al.Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma patients[J].J Clin Oncol,2018,36:2006.
28 David Reardon TK,Dietrich J,Dietrich J,et al.Atim-12.Phase 2 study to evaluate the clinical efficacy and safety of Medi4736(Durvalumab)in patients with Bevacizumab-refractory recurrent glioblastoma[J].Neuro Oncol,2017,19(suppl 6):28.
29 Puzanov I,Diab A,Abdallah K,et al.Managing toxicities associated with immune checkpoint inhibitors:consensus recommendations from the Society for Immunotherapy of Cancer(SITC)Toxicity Management Working Group[J].J Immunother Cancer,2017,5(1):95.
30 Eigentler TK,Hassel JC,Berking C,et al.Diagnosis,monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J].Cancer Treat Rev,2016,45:7-18.
31 Iorgulescu JB,Gokhale PC,Speranza MC,et al.Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma[J].Clin Cancer Res,2021,27(1):276-287.

[1]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[2]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[3]	杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.
[4]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[5]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[6]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[7]	王明明, 陈晓品. 抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 179-183.
[8]	李瑞阳,方琳(综述),张艳桥(审校). 食管癌免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 41-45.
[9]	刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.
[10]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[11]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[12]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[13]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[14]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[15]	姚洋张艳桥. 胃癌免疫检查点抑制剂作用机制及最新研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 371-375.

PD-1/PD-L1免疫检查点抑制剂在多形性胶质母细胞瘤中的研究进展

Research progress in PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma multiforme

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价